A Framework for Comparing R&D Productivity at Big Pharma Companies vs. Biotech Startups.
DOI:
文献链接:
其他信息:
R Murphey
Journal of Commercial Biotechnology, 2020
go.gale.com
Biopharmaceutical research and development (R&D) productivity has been steadily declining for several decades. Preliminary evidence suggests that this trend is stabilizing or reversing. one hypothesis explaining this improvement in R&D productivity is that the industry has shifted early-stage R&D activity from large multinational pharmaceutical companies to more smaller venture-backed startup companies. We examine recent trends in FDA approvals and biopharmaceutical R&D investment to develop a framework to evaluate …